FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016022909> ?p ?o ?g. }

• W2016022909 endingPage "209" @default.
• W2016022909 startingPage "203" @default.
• W2016022909 abstract "What is already known about this subject • Three previous epidemiological studies found an increased risk of severe skin and soft tissue infectious complications associated with exposure to NSAIDs in children with varicella. • In vitro studies demonstrated that decreases in defences against infections induced by NSAIDs could be due to impairment of neutrophil blood cell function. What this study adds • The use of NSAIDs is associated with an increased risk of severe skin and soft tissue complication of varicella in children. • The use of NSAIDs is also associated with a small increased risk of such complications in zoster disease in adults and the elderly. • This study supports the limited prescription of NSAIDs in VZV infection. Aims To assess the risk of severe skin and soft tissue complications associated with the use of nonsteroidal anti‐inflammatory drugs (NSAIDs) in treating patients with varicella zoster virus infection. Methods The design was a nested case‐control study, with matching for age and practice. The setting was primary care in the United Kingdom (United Kingdom's General Practice Research Database). Two population‐based cohorts of all patients with a primary varicella ( n = 140 111) or zoster ( n = 108 257) diagnosis during 1994–2005 were followed up for 2 months after diagnosis. Main outcome measures of severe skin or soft tissue complications (mostly cellulitis and abscess) associated with current NSAID or paracetamol use were estimated, and adjusted for potential confounding factors, including sex, drug use, and comorbidity. Results In patients with varicella, there were 386 cases of severe skin or soft tissue complications (rate 2.8 per 1000) during the 2 month follow‐up period (mean age 10.7 years). The rate of complications associated with exposure to NSAIDs was increased (rate ratio 4.9; 95% CI 2.1, 11.4). In patients with zoster disease, there were 681 cases of severe skin or soft tissue complications (rate 6.3 per 1000) during the 2 month follow‐up (mean age 60.9 years). The rate ratio of complications associated with exposure to NSAIDs was 1.6 (95% CI 1.1, 2.4). In both conditions, there was no increased risk of complication associated with a current exposure to paracetamol. Conclusions The use of NSAIDs is associated with an elevated risk of severe skin and soft tissue complications of varicella zoster virus infection, mostly in children with varicella." @default.
• W2016022909 created "2016-06-24" @default.
• W2016022909 creator A5008217187 @default.
• W2016022909 creator A5026880947 @default.
• W2016022909 creator A5041831769 @default.
• W2016022909 date "2007-08-15" @default.
• W2016022909 modified "2023-10-16" @default.
• W2016022909 title "Nonsteroidal anti-inflammatory drug use and the risk of severe skin and soft tissue complications in patients with varicella or zoster disease" @default.
• W2016022909 cites W1591786310 @default.
• W2016022909 cites W1691887444 @default.
• W2016022909 cites W1981384769 @default.
• W2016022909 cites W2001426216 @default.
• W2016022909 cites W2011744567 @default.
• W2016022909 cites W2012784204 @default.
• W2016022909 cites W2013427032 @default.
• W2016022909 cites W2023954230 @default.
• W2016022909 cites W2033094138 @default.
• W2016022909 cites W2040492681 @default.
• W2016022909 cites W2055056936 @default.
• W2016022909 cites W2059263921 @default.
• W2016022909 cites W2059920237 @default.
• W2016022909 cites W2063834545 @default.
• W2016022909 cites W2066617285 @default.
• W2016022909 cites W2070888339 @default.
• W2016022909 cites W2075101338 @default.
• W2016022909 cites W2078707956 @default.
• W2016022909 cites W2079396916 @default.
• W2016022909 cites W2091680344 @default.
• W2016022909 cites W2103442327 @default.
• W2016022909 cites W2106538704 @default.
• W2016022909 cites W2113227121 @default.
• W2016022909 cites W2138421921 @default.
• W2016022909 cites W2140682087 @default.
• W2016022909 cites W2148223907 @default.
• W2016022909 cites W2149679517 @default.
• W2016022909 cites W2157164709 @default.
• W2016022909 cites W2157604999 @default.
• W2016022909 cites W2167611650 @default.
• W2016022909 cites W2167950733 @default.
• W2016022909 cites W2620052693 @default.
• W2016022909 cites W4211188326 @default.
• W2016022909 cites W4235256988 @default.
• W2016022909 doi "https://doi.org/10.1111/j.1365-2125.2007.02997.x" @default.
• W2016022909 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2291221" @default.
• W2016022909 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18251759" @default.
• W2016022909 hasPublicationYear "2007" @default.
• W2016022909 type Work @default.
• W2016022909 sameAs 2016022909 @default.
• W2016022909 citedByCount "97" @default.
• W2016022909 countsByYear W20160229092012 @default.
• W2016022909 countsByYear W20160229092013 @default.
• W2016022909 countsByYear W20160229092014 @default.
• W2016022909 countsByYear W20160229092015 @default.
• W2016022909 countsByYear W20160229092016 @default.
• W2016022909 countsByYear W20160229092017 @default.
• W2016022909 countsByYear W20160229092018 @default.
• W2016022909 countsByYear W20160229092019 @default.
• W2016022909 countsByYear W20160229092020 @default.
• W2016022909 countsByYear W20160229092021 @default.
• W2016022909 countsByYear W20160229092022 @default.
• W2016022909 crossrefType "journal-article" @default.
• W2016022909 hasAuthorship W2016022909A5008217187 @default.
• W2016022909 hasAuthorship W2016022909A5026880947 @default.
• W2016022909 hasAuthorship W2016022909A5041831769 @default.
• W2016022909 hasBestOaLocation W20160229092 @default.
• W2016022909 hasConcept C107130276 @default.
• W2016022909 hasConcept C126322002 @default.
• W2016022909 hasConcept C136948725 @default.
• W2016022909 hasConcept C141071460 @default.
• W2016022909 hasConcept C142724271 @default.
• W2016022909 hasConcept C16005928 @default.
• W2016022909 hasConcept C203014093 @default.
• W2016022909 hasConcept C204787440 @default.
• W2016022909 hasConcept C2426938 @default.
• W2016022909 hasConcept C2522874641 @default.
• W2016022909 hasConcept C2775983603 @default.
• W2016022909 hasConcept C2776159415 @default.
• W2016022909 hasConcept C2776334287 @default.
• W2016022909 hasConcept C2777238321 @default.
• W2016022909 hasConcept C2778866549 @default.
• W2016022909 hasConcept C2779001537 @default.
• W2016022909 hasConcept C2779134260 @default.
• W2016022909 hasConcept C2779489039 @default.
• W2016022909 hasConcept C2908647359 @default.
• W2016022909 hasConcept C523546767 @default.
• W2016022909 hasConcept C54355233 @default.
• W2016022909 hasConcept C71924100 @default.
• W2016022909 hasConcept C86803240 @default.
• W2016022909 hasConcept C98274493 @default.
• W2016022909 hasConcept C99454951 @default.
• W2016022909 hasConceptScore W2016022909C107130276 @default.
• W2016022909 hasConceptScore W2016022909C126322002 @default.
• W2016022909 hasConceptScore W2016022909C136948725 @default.
• W2016022909 hasConceptScore W2016022909C141071460 @default.
• W2016022909 hasConceptScore W2016022909C142724271 @default.
• W2016022909 hasConceptScore W2016022909C16005928 @default.
• W2016022909 hasConceptScore W2016022909C203014093 @default.
• W2016022909 hasConceptScore W2016022909C204787440 @default.

• next